Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

Last updated: August 6, 2024
Sponsor: Sanoculis Ltd
Overall Status: Active - Recruiting

Phase

N/A

Condition

Open Angle Glaucoma

Glaucoma

Treatment

Minimally Invasive Micro Sclerostomy Device

Clinical Study ID

NCT06313749
MMS-US-1
  • Ages 40-85
  • All Genders

Study Summary

The goal of this clinical trial is to show non-inferiority of the MIMS® device/procedure with Mitomycin-C, in terms of its surgical success rate, compared to trabeculectomy with Mitomycin-C in subjects diagnosed with primary open angle glaucoma, whose intraocular pressure is not controlled despite polypharmacy.

Eligible screened participants will undergo the MIMS® procedure and will be followed for a period of 12 months in this single-arm study. Investigators will compare the results of this study to the surgical success rate of traditional trabeculectomy with Mitomycin-C.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male or female, ≥ 40 years to ≤ 85 years old

  2. Inadequately controlled primary open angle glaucoma with screening mean diurnal IOP of ≥ 21 mmHg and ≤ 40 mmHg despite polypharmacy

  3. Primary open angle glaucoma diagnosis based on:

  4. Visual field mean deviation of -3dB or worse and

  5. Glaucomatous optic nerve damage as evidenced by optic disc or retinal nerve fiber layer structural abnormalities documented on slit lamp stereo biomicroscopy or in stereo disc photos

  6. Presence of healthy, free, and mobile conjunctiva in the target quadrant

  7. Prior ab interno conjunctival-sparing glaucoma procedures were conducted more than 6 months prior to enrollment (e.g., iStent, Trabectome, gonioscopy-assisted transluminal trabeculectomy [GATT])

  8. Subject is able and willing to attend all scheduled follow-up exams

  9. Subject understands and signs the informed consent

Study Design

Total Participants: 129
Treatment Group(s): 1
Primary Treatment: Minimally Invasive Micro Sclerostomy Device
Phase:
Study Start date:
June 01, 2024
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Glaucoma Associates of Texas

    Dallas, Texas 75231
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.